Genocea Biosciences Inc. (NASDAQ:GNCA) has received an average rating of “Buy” from the five brokerages that are presently covering the company. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $14.25.
Several research firms recently commented on GNCA. FBR & Co reaffirmed a “buy” rating on shares of Genocea Biosciences in a report on Monday, August 8th. Piper Jaffray Cos. cut their price target on Genocea Biosciences from $9.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, September 29th. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price target on shares of Genocea Biosciences in a report on Thursday, November 3rd. Finally, Zacks Investment Research raised Genocea Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, November 8th.
A number of large investors have recently bought and sold shares of GNCA. Northern Trust Corp boosted its stake in Genocea Biosciences by 24.3% in the third quarter. Northern Trust Corp now owns 34,636 shares of the company’s stock valued at $177,000 after buying an additional 6,763 shares during the period. Northpointe Capital LLC boosted its stake in Genocea Biosciences by 90.2% in the third quarter. Northpointe Capital LLC now owns 1,438,286 shares of the company’s stock valued at $7,364,000 after buying an additional 682,269 shares during the period. Paloma Partners Management Co acquired a new stake in Genocea Biosciences during the second quarter valued at about $334,000. Alpine Partners VI LLC acquired a new stake in Genocea Biosciences during the second quarter valued at about $120,000. Finally, TFS Capital LLC acquired a new stake in Genocea Biosciences during the second quarter valued at about $133,000. 58.67% of the stock is owned by institutional investors.
Shares of Genocea Biosciences (NASDAQ:GNCA) opened at 4.31 on Tuesday. Genocea Biosciences has a 12 month low of $2.56 and a 12 month high of $8.07. The firm’s 50-day moving average price is $3.96 and its 200-day moving average price is $4.43. The company’s market capitalization is $122.32 million.
Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings results on Thursday, November 3rd. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.01. Genocea Biosciences had a negative net margin of 5,121.17% and a negative return on equity of 57.92%. Equities research analysts expect that Genocea Biosciences will post ($1.64) EPS for the current year.
About Genocea Biosciences
Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.
Receive News & Ratings for Genocea Biosciences Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.